.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Dow
Medtronic
Johnson and Johnson
McKesson
McKinsey
Merck
Queensland Health
UBS
Cipla

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206162

« Back to Dashboard

NDA 206162 describes LYNPARZA, which is a drug marketed by Astrazeneca Pharms and is included in two NDAs. It is available from one supplier. There are eight patents protecting this drug. Additional details are available on the LYNPARZA profile page.

The generic ingredient in LYNPARZA is olaparib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the olaparib profile page.

Summary for 206162

Tradename:1
Applicant:1
Ingredient:1
Patents:7

Pharmacology for NDA: 206162

Suppliers and Packaging for NDA: 206162

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LYNPARZA olaparib CAPSULE;ORAL 206162 NDA AstraZeneca Pharmaceuticals LP 0310-0657 0310-0657-58 112 CAPSULE in 1 BOTTLE (0310-0657-58)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength50MG
Approval Date:Dec 19, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 19, 2019
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Dec 19, 2021
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY
Patent:► SubscribePatent Expiration:Apr 29, 2022Product Flag?YSubstance Flag?YDelist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Argus Health
US Army
Citi
Fuji
Novartis
Merck
Baxter
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot